NewAmsterdam Pharma (NAMS) Stock Analysis

What NewAmsterdam Pharma does

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Key metrics

ETFs linked to NAMS

Broad-market and Healthcare sector ETFs an investor holding NewAmsterdam Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NAMS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NewAmsterdam Pharma?

NewAmsterdam Pharma trades under the ticker NAMS on NASDAQ.

Which exchange is NAMS listed on?

NAMS is listed on NASDAQ.

What sector does NewAmsterdam Pharma operate in?

NewAmsterdam Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NAMS in a portfolio?

PortView shows NAMS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.